Drugs / IMA901
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00523159 | May 2007 → Aug 2009 | renal cell carcinoma | Immatics Biotechnologies GmbH | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01265901 | Dec 2010 → Jul 2015 | renal cell carcinoma | Immatics Biotechnologies GmbH | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2015-09-27 | Immatics Biotechnologies GmbH | Results Immatics announces results of IMPRINT phase 3 clinical trial investigating the addition of IMA901 to standard first-line therapy with sunitinib for advanced/metastatic RCC immatics.com ↗
The phase 3 trial did not meet its primary endpoint of showing an overall survival benefit of IMA901 in combination with sunitinib compared with sunitinib alone in this patient population. |
| 2012-11-08 | Immatics Biotechnologies GmbH | Regulatory Immatics’ renal cancer vaccine IMA901 completes phase 3 patient recruitment and is granted US orphan drug designation by the FDA immatics.com ↗ |
| 2012-06-29 | Immatics Biotechnologies GmbH | Results immatics announces publication of IMA901 cancer vaccine data in Nature Medicine: immune response associates with longer survival immatics.com ↗
The paper highlights that renal cell carcinoma patients experience longer survival times when their immune system produces an immune response to more than one of the peptides in IMA901, the first multi-peptide therapeutic cancer vaccine for RCC. |
| 2012-06-01 | Immatics Biotechnologies GmbH | Results immatics presents encouraging overall survival data from a phase 2 study in Advanced Colorectal Cancer at the ASCO Annual Meeting immatics.com ↗
The immatics study also showed that patients who developed immune responses to two or more of the tumor associated peptides (TUMAPs) in IMA910 correlate with longer overall survival times. |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMA901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00523159 ↗ |
| Modality | Vaccine | “the cancer vaccine IMA901” NCT00523159 ↗ |